Anatibant
Alternative Names: LF 160687; LF16-0687MS; XY-2405Latest Information Update: 03 Mar 2010
At a glance
- Originator Fournier Pharma
- Developer Fournier Pharma; London School of Hygiene & Tropical Medicine
- Class Analgesics; Anti-inflammatories; Quinolines; Small molecules
- Mechanism of Action Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Brain injuries
Most Recent Events
- 15 Mar 2007 Xytis initiates enrolment in the BRAIN trial for traumatic brain injury
- 11 Jan 2007 Phase-II clinical trials in Head injuries in South Africa (SC)
- 11 Jan 2007 Phase-II clinical trials in Head injuries in United Kingdom (SC)